enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Buy” from Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has been assigned an average rating of “Buy” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $25.22.

A number of equities research analysts have recently issued reports on ENGN shares. Raymond James started coverage on shares of enGene in a report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price target on the stock. Morgan Stanley lowered their target price on shares of enGene from $37.00 to $34.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 11th. JMP Securities restated a “market outperform” rating and set a $18.00 price target on shares of enGene in a research report on Monday, December 23rd. UBS Group downgraded enGene from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $34.00 to $7.00 in a research report on Friday, February 14th. Finally, Piper Sandler started coverage on enGene in a research note on Tuesday, February 18th. They set an “overweight” rating and a $26.00 price objective for the company.

enGene Price Performance

Shares of NASDAQ ENGN opened at $5.21 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The stock has a market cap of $265.59 million, a PE ratio of -8.98 and a beta of -0.61. The stock has a fifty day moving average of $6.29 and a 200-day moving average of $7.07.

enGene (NASDAQ:ENGN) last issued its earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06. Equities research analysts anticipate that enGene will post -1.56 earnings per share for the current year.

Institutional Trading of enGene

A number of hedge funds have recently made changes to their positions in ENGN. Toronto Dominion Bank bought a new position in enGene in the fourth quarter valued at $97,000. VR Adviser LLC boosted its holdings in shares of enGene by 41.5% in the 4th quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock worth $33,559,000 after purchasing an additional 1,480,573 shares in the last quarter. Vestal Point Capital LP bought a new position in shares of enGene during the 4th quarter valued at about $2,460,000. Sphera Funds Management LTD. purchased a new position in shares of enGene during the 4th quarter valued at about $3,724,000. Finally, Point72 Asset Management L.P. lifted its position in enGene by 84.7% in the 4th quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company’s stock worth $8,145,000 after buying an additional 561,797 shares during the last quarter. 64.16% of the stock is owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.